Trial Profile

Phase IB Study of Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Lung cancer; Meningeal carcinomatosis; Nasopharyngeal cancer; Ovarian cancer; Pancreatic cancer
Focus Adverse reactions

Most Recent Events

27 Nov 2024 Status changed from active, no longer recruiting to completed.
06 Jun 2023 Results (n=15) reporting safety and efficacy data presented at the 59th Annual Meeting of the American Society of Clinical Oncology
01 Aug 2022 Planned primary completion date changed from 19 Jul 2022 to 6 Aug 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com